- Lobbying
- Lobbying by GTx, Inc.
Lobbying Relationship
Bills mentioned
S.2742: SARMs Control Act of 2018
Sponsor: Orrin G. Hatch (R-Utah)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Heather Podesta | Counsel, Representative Robert Matsui (2003); Counsel, Representative Earl Pomeroy (2002-2003); Legislative Fellow, Senator Bill Bradley (1993-1994); Research Assistant, Congressional Budget Office (1992) |
Eric Rosen | Asst US Atty, N. Dist of CA, Dept of Justice (2006-2007) Counsel, Sen. Judiciary Comm (2001-2006); Leg. Dir, Rep. Anthony Weiner (1999-2001); Dep Dir, Dept of Justice Office of Intergovt Affair (1997-1999); Leg. Asst, Rep. Chet Atkins (1992-1993) |
Benjamin Klein | Legislative Director, Senator Byron Dorgan (2007-2010); Legislative Assistant, Senator Byron Dorgan (2005-2007) |
Katie Wise | Leg. Dir, Rep. Vern Buchanan (2014-2015) Leg. Dir, Rep. Mike Fitzpatrick (2013-2014) Sr. Legislative Asst, Rep. Mike Fitzpatrick (2011-2013) Legislative Correspondent/Asst, Rep. Mary Fallin (2010-2011) Staff Asst, Rep. Mary Fallin (2009-2010) |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Pharmacy
Registration
Issue(s) they said they’d lobby about: Educate policymakers about targeted hormone receptor-based therapies..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate